Evidence map›Paper›PMID 22532833›Full record

ArticlePloS one2012

Loss of maternal CTCF is associated with peri-implantation lethality of Ctcf null embryos.

James M Moore, Natalia A Rabaia, Leslie E Smith, Sara Fagerlie, Kay Gurley, Dmitry Loukinov, Christine M Disteche, Steven J Collins, Christopher J Kemp, Victor V Lobanenkov and 1 more

Abstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 88 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
88citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

88 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. An updated catalog ofFrontiers in molecular neuroscience · 2023
    Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

28 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

James M MooreHuman Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
Natalia A Rabaia
Leslie E Smith
Sara Fagerlie
Kay Gurley
Dmitry Loukinov
Christine M Disteche
Steven J Collins
Christopher J Kemp
Victor V Lobanenkov
Galina N Filippova

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Marian Esvelt · 1985 to 2026
$296.4M
Normal and Pathologic Functions of CTCF and Its Distinct Classes of DNA-targetsZIAAI000860 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LOBANENKOV, VICTOR · 2009 to 2025
$15.4M
Regulation of CTCF Functions and Target Sites by Cancer/Testis-specific CTCF Like BORIS FactorZIAAI001021 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LOBANENKOV, VICTOR · 2009 to 2025
$12.7M
Mouse X InactivationR01GM046883 · NIGMS · UNIVERSITY OF WASHINGTON · PI DISTECHE, CHRISTINE M. · 1992 to 2018
$5.9M
STRUCTURE AND FUNCTION OF CTCF--TRANSGENIC MICE STUDIESR01CA068360 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI FILIPPOVA, GALINA N · 1996 to 2007
$3.2M
NCI NIH HHS CA68360NCI NIH HHS P30 CA015704NCI NIH HHS R01 CA068360NIGMS NIH HHS GM 46883NIGMS NIH HHS R01 GM046883
6 · The paper itself

Abstract

CTCF is a highly conserved, multifunctional zinc finger protein involved in critical aspects of gene regulation including transcription regulation, chromatin insulation, genomic imprinting, X-chromosome inactivation, and higher order chromatin organization. Such multifunctional properties of CTCF suggest an essential role in development. Indeed, a previous report on maternal depletion of CTCF suggested that CTCF is essential for pre-implantation development. To distinguish between the effects of maternal and zygotic expression of CTCF, we studied pre-implantation development in mice harboring a complete loss of function Ctcf knockout allele. Although we demonstrated that homozygous deletion of Ctcf is early embryonically lethal, in contrast to previous observations, we showed that the Ctcf nullizygous embryos developed up to the blastocyst stage (E3.5) followed by peri-implantation lethality (E4.5-E5.5). Moreover, one-cell stage Ctcf nullizygous embryos cultured ex vivo developed to the 16-32 cell stage with no obvious abnormalities. Using a single embryo assay that allowed both genotype and mRNA expression analyses of the same embryo, we demonstrated that pre-implantation development of the Ctcf nullizygous embryos was associated with the retention of the maternal wild type Ctcf mRNA. Loss of this stable maternal transcript was temporally associated with loss of CTCF protein expression, apoptosis of the developing embryo, and failure to further develop an inner cell mass and trophoectoderm ex vivo. This indicates that CTCF expression is critical to early embryogenesis and loss of its expression rapidly leads to apoptosis at a very early developmental stage. This is the first study documenting the presence of the stable maternal Ctcf transcript in the blastocyst stage embryos. Furthermore, in the presence of maternal CTCF, zygotic CTCF expression does not seem to be required for pre-implantation development.

Indexed as

AllelesAnimalsApoptosisBlastocystCCCTC-Binding FactorEmbryo ImplantationEmbryonic DevelopmentMiceMice, KnockoutRepressor ProteinsCCCTC-Binding FactorCtcf protein, mouseRepressor Proteins

Identifiers

PMID22532833
PMCPMC3332108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.